The DOI matches its Crossref record.
Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011
Open accessAbstract
Purpose: This study sought to define and identify drivers of trends in cost and use of targeted therapeutics among privately insured nonelderly patients with cancer receiving chemotherapy between 2001 and 2011. Methods: We classified oncology drugs as targeted oral anticancer medications, targeted intravenous anticancer medications, and all others. Using the LifeLink Health Plan Claims Database, we studied and disaggregated trends in use and in insurance and out-of-pocket payments per patient per month and during the first year of chemotherapy. Results: We found a large increase in the use of targeted intravenous anticancer medications and a gradual increase in targeted oral anticancer medications; targeted therapies accounted for 63% of all chemotherapy expenditures in 2011. Insurance payments per patient per month and in the first year of chemotherapy for targeted oral anticancer medications more than doubled in 10 years, surpassing payments for targeted intravenous anticancer medications, which remained fairly constant throughout. Substitution toward targeted therapies and growth in drug prices both at launch and postlaunch contributed to payer spending growth. Out-of-pocket spending for targeted oral anticancer medications was ≤ half of the amount for targeted intravenous anticancer medications. Conclusion: Targeted therapies now dominate anticancer drug spending. More aggressive management of pharmacy benefits for targeted oral anticancer medications and payment reform for injectable drugs hold promise. Restraining the rapid rise in spending will require more than current oral drug parity laws, such as value-based insurance that makes the benefits and costs transparent and involves the patient directly in the choice of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Financial Hardships Experienced by Cancer Survivors: A Systematic Review
Altice, C. K., Banegas, M. P., Tucker-Seeley, R. D., & Yabroff, K. R. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw205 · Cited by 864
Witte, J., Mehlis, K., Surmann, B., Lingnau, R., Damm, O., Greiner, W., & Winkler, E. C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz140 · Cited by 271
Navigating financial toxicity in patients with cancer: A multidisciplinary management approach
Smith, G. L., Banegas, M. P., Acquati, C., Chang, S., Chino, F., Conti, R. M., Greenup, R. A., Kroll, J. L., Liang, M. I., Pisu, M., et al. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21730 · Cited by 260
Patient and interest organizations’ views on personalized medicine: a qualitative study
Budin-Ljøsne, I., & Harris, J. R. (2016) · BMC Medical Ethics · doi:10.1186/s12910-016-0111-7 · Cited by 32
“For instance, the prices of new targeted drugs have steadily increased during the last decade [26] and health care systems frequently deny patients access to such drugs because of financial constraints unless the patients can pay out-of-pocket [27, 28].”
Metadata
- Authors
- Shih, Y.-C. T., Smieliauskas, F., Geynisman, D. M., Kelly, R. J., & Smith, T. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-07-01
- Volume
- 33
- Issue
- 19
- Pages
- 2190-2196
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2107779395
- Cited by
- 163
- References
- 0
- FWCI
- 44.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. https://app.cochat.ai/papers/10.1200/jco.2014.58.2320
- The paper
- Shih, Y.-C. T., Smieliauskas, F., Geynisman, D. M., Kelly, R. J., & Smith, T. J. (2015). Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.58.2320
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.